<DOC>
	<DOC>NCT00948389</DOC>
	<brief_summary>To determine whether dasatinib plus lomustine are effective for treatment of recurrent glioblastoma</brief_summary>
	<brief_title>Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Patients with histological or cytological proven glioblastoma multiforme Recurrent or progressive disease documented by magnetic resonance imaging (MRI) World Health Organization (WHO) Performance status 0 2 Patient may have been operated for recurrence For non operated patients, recurrent disease must be at least one bidimensionally measurable target lesion with one diameter of at least 2cm Patients must be on a stable or decreasing dose of corticosteroids for at least 1 week prior to baseline MRI Patients with histological or cytological proven glioblastoma multiforme Completion of radiotherapy to the brain less than 3 months prior to registration/randomization Prior treatment with high dose radiotherapy, stereotactic radiosurgery or internal radiation therapy Previous or current malignancy at other sites within prior 3 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>